Feldman E C
J Am Vet Med Assoc. 1985 Jul 1;187(1):49-53.
Twenty-one dogs with hyperadrenocorticism were studied. Six dogs had functioning adrenocortical tumors and 15 had pituitary-dependent hyperadrenocorticism. Each dog was evaluated, using endogenous plasma ACTH, ACTH stimulation, dexamethasone screening, dexamethasone suppression, and combined dexamethasone suppression/ACTH stimulation tests. The ACTH stimulation portion of the combined test was less reliable as a screening test in diagnosing hyperadrenocorticism than was the isolated ACTH stimulation test or the dexamethasone screening test. The dexamethasone suppression portion of the combined test was less reliable in distinguishing dogs with adrenocortical tumors from those with pituitary-dependent hyperadrenocorticism than was the endogenous ACTH or isolated dexamethasone suppression test. The combined test is not recommended for use. The ACTH stimulation test is the recommended screening test because of its diagnostic reliability and its subsequent importance as a base line in determining success of mitotane therapy.
对21只患有肾上腺皮质功能亢进的犬进行了研究。6只犬患有功能性肾上腺皮质肿瘤，15只患有垂体依赖性肾上腺皮质功能亢进。每只犬都通过内源性血浆促肾上腺皮质激素（ACTH）、ACTH刺激、地塞米松筛查、地塞米松抑制以及联合地塞米松抑制/ACTH刺激试验进行评估。联合试验中ACTH刺激部分作为诊断肾上腺皮质功能亢进的筛查试验，不如单独的ACTH刺激试验或地塞米松筛查试验可靠。联合试验中地塞米松抑制部分在区分患有肾上腺皮质肿瘤的犬和垂体依赖性肾上腺皮质功能亢进的犬方面，不如内源性ACTH或单独的地塞米松抑制试验可靠。不建议使用联合试验。由于ACTH刺激试验具有诊断可靠性且作为确定米托坦治疗成功的基线具有后续重要性，因此推荐将其作为筛查试验。
